Cefetamet pivoxil in otitis media
A Quevedo1, R Sossouhounto, M Kissling
1Posto de Urgencia, Rio de Janeiro, Brazil.
Insights
Cefetamet pivoxil demonstrated superior efficacy and safety in treating acute otitis media in children compared to cefaclor. This antibiotic offers a promising alternative for pediatric ear infections.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology and Therapeutics
- Otolaryngology
Background:
- Acute otitis media (AOM) is a common childhood infection requiring effective antibiotic treatment.
- Evaluating alternative antibiotic regimens is crucial for optimizing AOM management and combating resistance.
Purpose of the Study:
- To compare the efficacy and safety of cefetamet pivoxil versus cefaclor in children with AOM.
- To assess bacteriological and clinical cure rates, as well as adverse event profiles.
Main Methods:
- Multicentre, open-label, randomized, parallel-group study involving 270 children aged 1-15 years.
- Patients received either cefetamet pivoxil (10 mg/kg b.i.d.) or cefaclor (13.5 mg/kg t.i.d.) for 7 days.
- Outcomes included bacteriological and clinical cure rates, and incidence of adverse events.
Main Results:
- Cefetamet pivoxil achieved 100% bacteriological cure (44/44) compared to 86% (24/28) for cefaclor.
- Clinical cure or improvement was higher with cefetamet pivoxil (97%; 117/121) versus cefaclor (90%; 104/115).
- Cefetamet pivoxil showed a lower incidence of adverse events (11% vs. 15%) and fewer treatment withdrawals (0.7% vs. 2.2%).
Conclusions:
- Cefetamet pivoxil is a highly effective and well-tolerated treatment option for acute otitis media in children.
- The study supports cefetamet pivoxil as a favorable alternative to cefaclor for pediatric AOM management.
Abstract:
In this multicentre, open, randomized, parallel-group study, 270 children with acute otitis media aged between 1 and 15 years were randomized to receive either cefetamet pivoxil 10 mg/kg b.i.d. for 7 days (n = 134) or cefaclor 13.5 mg/kg t.i.d. for 7 days (n = 136). At the end of treatment, bacteriological cure occurred in 44/44 (100%) patients receiving cefetamet pivoxil and 24/28 (86%) patients receiving cefaclor. Clinical cure or improvement was experienced by 117/121 (97%) of patients receiving cefetamet pivoxil and 104/115 (90%) patients in the cefaclor group. Adverse side effects, mainly gastrointestinal disorders, occurred in 11% of patients in the cefetamet pivoxil group compared with 15% of patients in the cefaclor group. All adverse events were of mild or moderate severity and subsided rapidly after treatment. Premature treatment withdrawals occurred in 0.7% of patients who received cefetamet pivoxil and in 2.2% of those who received cefaclor.
Related Concept Videos
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:30Tonsillitis I: Introduction
Etiology
Three primary contributing factors have been identified.
01:26Tonsillitis II: Management
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:24Bacterial Meningitis
01:27Streptococcal Pharyngitis